Summarized by Masters of Longevity from Longevity Technology.
A Latus Bio model links MSH3 suppression to slowed somatic CAG expansion and delayed progression.
Key Takeaways
- A computational model is reported to predict delayed motor onset.
- Preclinical AAV therapy was found to reduce MSH3 in primate striatum.
- Short animal studies have not established long-term human benefit.
